Alseres Pharmaceuticals, Inc.

ALSE

US0211522026

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 02:06:50 2023-10-18 pm EDT			5-day change	1st Jan Change
0.005 ^USD	-50.00%		-.--%	-.--%

2015	Alseres Pharmaceuticals, Inc. cancelled the acquisition of E-IACFT Injection from Navidea Biopharmaceuticals, Inc.	CI
2015	Alseres Pharmaceuticals, Inc. will Change its Ticker to ALSE from ALSED	CI

Alseres Pharmaceuticals, Inc. will Change its Ticker to ALSE from ALSED

January 29, 2015 at 12:00 am EST

Effective January 29, 2015, Alseres Pharmaceuticals, Inc. will change its Pink Sheets LLC stock ticker symbol to ALSE from ALSED.

Latest news about Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. cancelled the acquisition of E-IACFT Injection from Navidea Biopharmaceuticals, Inc.	15-04-21	CI
Alseres Pharmaceuticals, Inc. will Change its Ticker to ALSE from ALSED	15-01-29	CI
Alseres Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	14-04-10	CI
Alseres Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	13-04-01	CI
Alseres Pharmaceuticals, Inc. Licenses Altropane Rights to Navidea Biopharmaceuticals	12-08-06	CI
Alseres Pharmaceuticals, Inc. entered into an agreement to acquire E-IACFT Injection from Navidea Biopharmaceuticals, Inc for $3.4 million.	12-08-06	CI
Alseres Pharmaceuticals, Inc. Taken Out Licensing Agreement with Alseres Pharmaceuticals, Inc	12-08-02	CI
Alseres Pharmaceuticals, Inc. Reports License of Altropane(R) Worldwide Rights to Navidea Biopharmaceuticals, Inc	12-07-31	CI
Alseres Pharmaceuticals, Inc. announced that it has received $34.4 million in funding from Highbridge Capital Management, LLC, Ingalls & Snyder LLC, and other investors.	12-07-17	CI
Navidea Biopharmaceuticals to Continue its Diligence Through the End of July 2012 with Alseres Pharmaceuticals, Inc. to License E-IAFCT Injection	12-07-02	CI
Alseres Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	12-03-29	CI
Navidea Biopharmaceuticals, Inc. Signs Option Agreement with Alseres Pharmaceuticals, Inc., to License Altropane	12-01-26	CI

Chart Alseres Pharmaceuticals, Inc.

Duration

Period

More charts

Alseres Pharmaceuticals, Inc. is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). The Company's lead product candidate is Altropane. The Company's Altropane product is a molecular imaging agent used to diagnose Parkinson's disease and dementia. The Company is focused on entering into partnerships to ensure development and commercialization of its product.

Sector

Pharmaceuticals

More about the company